These efforts showed that the expression levels of immune checkpoints or their ligands, such as PD-1 or PD-L1, antigen presentation, mismatch repair deficiency, tumour mutational burden, mutational signatures, lymphocyte infiltration, microbiome status and other currently used biomarkers have limited predictive power.7 Here, PDCD1 is linked to neoplasm.